Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.44 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | JAK1 | P23458 | 4/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30473749 | 1.00 | LMNA (0.51) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL9205078 | 0.93 | LMNA (0.56) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL5452621 | 0.93 | LMNA (0.60) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL5458071 | 0.92 | LMNA (0.61) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL797230 | 0.92 | LMNA (0.61) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL5670409 | 0.90 | RPS6KB1 (0.48) | LMNAHTTPAK1PKMHSD17B10 | |
| Hydrochloric Acid SCHEMBL1748687 | 0.89 | RPS6KB1 (0.47) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL6643407 | 0.81 | GBA1 (0.39) | LMNAHTTPAK1HPGDS | |
| SCHEMBL133156 | 0.78 | CHUK (0.45) | LMNAHTTPAK1PKMHSD17B10 | |
| SCHEMBL30590050 | 0.78 | CHUK (0.45) | LMNAHTTPAK1PKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| CN-119278043-A | Nucleoside LINE-1 inhibitors | 转位治疗股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2023192491-A2 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-11-04 | — | — | US | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3040337-B1 | 2, 6-DI-NITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ZHEJIANG MED XINCHANG PHARM (CN) | 2019-04-17 | — | — | EP | disclosed |
| CN-104418858-B | Nitrogenous substituted purine derivative of 2,6- bis- and preparation method thereof and its pharmaceutical composition and application | 浙江医药股份有限公司新昌制药厂 | 2018-12-11 | — | — | CN | disclosed |
| WO-2018133835-A1 | NUCLEOSIDE ANALOGUE REGULATING MAMMALIAN CIRCADIAN RHYTHM | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018133854-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-07-26 | — | — | WO | disclosed |
| US-5420115-A | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides | BURROUGHS WELLCOME CO. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0286425-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-11 | — | — | EP | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0417999-A1 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-03-20 | — | — | EP | disclosed |
| EP-0366287-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-05-02 | — | — | EP | disclosed |
| EP-0317128-A2 | Anti-HIV Pyrimidine Nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-05-24 | — | — | EP | disclosed |
| EP-0294114-A2 | Antiviral compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-07 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | LMNA 599/4885HTT 3291/4885PAK1 197/4885 |
| US-20260035403-A1 | NUCLEOSIDE LINE-1 INHIBITORS | L3MBTL1, TDP1, TRDMT1 | LMNA 71/4885HTT 214/4885PAK1 2953/4885 |
| US-20210338706-A1 | ADENOSINE ANALOG AND ITS USE IN REGULATING THE CIRCADIAN CLOCK | PER2, CRY1, ADORA2A | LMNA 2993/4885HTT 4069/4885PAK1 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.